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SUMMARY
Opportunistic diseases (OD) are the most common cause of death in AIDS patients. To access the incidence of OD and survival
in advanced immunodeficiency, we included 79 patients with AIDS treated at Hospital Evandro Chagas (FIOCRUZ) from September
1997 to December 1999 with at least one CD4 count  100 cells/mm3. The incidence of OD was analyzed by Poisson’s regression, and
survival by Kaplan Meier and Cox analysis, considering a retrospective (before CD4  100 cells/mm3) and a prospective (after CD4
 100 cells/mm3) period, and controlling for demographic, clinical and laboratory characteristics. The confidence interval estipulated
was 95%.
Mean follow-up period was 733 days (CI = 683-782). During the study 9 (11.4%) patients died. Survival from AIDS diagnosis
was a mean of 2589 days (CI = 2363-2816) and from the date of the CD4 count CD4  100 cells/mm3 was a mean of 1376 (CI = 1181-
1572) days. Incidence of OD was 0.51 pp/y before CD4  100 cells/mm3 and 0.29 pp/y after CD4  100 cells/mm3. A lower number
of ODs before CD4 < 100 cells/mm3 was associated with lower incidence rates after CD4  100 cells/mm3. AIDS diagnosis based on
CD4+ counts  200 cells/mm3 was associated with lower incidence rates after CD4  100 cells/mm3. Baseline CD4 counts above 50
cells/mm3 (HR = 0.13) and restoration of baseline CD4+ counts above 100 cells/mm3 (HR = 0.16) were associated with a lower risk of
death. Controling both variables, only restoration of baseline counts was statistically significant (HR = 0.22, p = 0.04).
We found a very low incidence of OD and long survival after CD4 < 100 cells/mm3. Survival was significantly associated with
restoration of baseline CD4 counts above 100 cells/mm3.
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INTRODUCTION
The introduction of highly active antiretroviral treatment (HAART)
has lowered incidence of opportunistic diseases (ODs)2, prolonged
survival3,23 and reduced AIDS-related hospital admissions21. HAART has
also had a beneficial effect on individuals with advanced
immunosuppression3. Little has been done, however, to explore the effects
of reconstituting CD4+ cells on OD incidence, especially among patients
at an advanced stage of immunodeficiency16.
Evaluation of the effect of universal distribution of anti-retrovirals
free-of-charge in São Paulo revealed a 50% reduction in AIDS-related
hospital admission and mortality rates18. However, the incidence of AIDS-
related events and the factors that may influence survival following this
measure have yet to be evaluated in Brazil.
OBJECTIVES
To identify the factors associated with morbidity and survival in
AIDS patients treated with HAART at an advanced stage of
immunodeficiency, as compared with before CD4 T cell counts dropped
below 100 cells/mm3.
PATIENTS AND METHODS
We conducted a bidirectional cohort study at the Evandro Chagas
Hospital Research Centre (Centro de Pesquisa Hospital Evandro Chagas,
CPqHEC) of the Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro,
from September 1, 1997 to December 7, 1999. The CPqHEC is an
institution that specializes in treating adults with HIV/AIDS or other
infectious diseases, and offers reference on clinical and laboratory
services.
Inclusion criteria: adult patients with at least an absolute CD4+
lymphocyte count of  100 cells/mm3 in peripheral blood.
Exclusion criteria: individuals monitored for less than 90 days at
the end of the study were excluded.
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Criterion for defining AIDS and related ODs: the CDC 1993
criterion was adopted4. This study however, did not take account of
bacterial pneumonias due to the large number of presumptive diagnoses
without bacteriological confirmation.
Data gathering: An initial interview was held to obtain retrospective
data on diagnoses of AIDS-indicator diseases, as well as prior
antiretroviral treatment. Whenever necessary, this information was
complemented by consulting medical records. The monthly prospective
evaluation recorded diagnoses of AIDS-related ODs, the antiretroviral
treatment used and laboratory data such as plasma HIV1-RNA load and
CD4+ cell count, which were repeated every four months.
CD4+ T cells were counted by flow cytometry (Epics XL, Coulter
Co, FL, USA), using TriTEST CD4 FITC/ CD8 PE/CD3 PerCP
monoclonal antibodies (BD Immunocytometry Systems, SJ, CA, USA).
Viral load was measured by NucliSens HIV-1 QT (NASBA Diagnostics,
Organon Teknika, Holland) in plasma samples. Both exams were assured
by the National Network for CD4 and Viral Load Evaluation, from the
National Coordination of Sexual Transmitted Diseases and AIDS,
Brazilian Ministry of Health.
Statistical analysis: this contemplated two periods: a prospective
period, measured in days, from inclusion in the study (date of the first
CD4 count below 100 cell/mm3) through to completion of the project,
death of the patient or loss of follow-up; and a retrospective period from
the AIDS diagnosis through to the CD4+ cell count of inclusion. OD
incidence was analyzed by Poisson regression, and survival by the Kaplan
Meier method. The risks associated with the variables were evaluated
by Cox regression.
Models were constructed and tested for the incidence of OD (Poisson
regression) and survival (Cox proportional harzard model) considering
the folowing characteristics: gender, age, the AIDS-defining criterion
(OD or CD4 counts  200 cells/mm3), start of antiretroviral treatment
with monotherapy double therapy or HAART, aggregate number of ODs
up to inclusion in the study, CD4+ cell count at the moment of inclusion
( 50, or >50/ < 100 cells/mm3), restoration of baseline CD4+ cell count
(at the 100 and 200 cells/mm3 cutoffs) and plasma virus loads over time
(< 10,000, < 30,000 and < 100,000 copies/ml). A 95% confidence interval
(CI) was stipulated.
Some OD were grouped by relative frequencies and the criterion of
severity associated with the diagnosis13,25 into: Group 1 - tuberculosis;
Group 2 - neurotoxoplasmosis, PCP, Isosporiasis, Cryptosporidiasis and
Kaposi’s sarcoma; Group 3 – DMAC or Cytomegalovirosis and Group
4 - Candidiasis of the esophagus, Cryptococcosis and Histoplasmosis.
The softwares used for analysis were SPSS 8.0 for Windows22 and
EGRET28.
RESULTS
Characteristics of the Cohort: The study included 79 individuals.
Mean age at AIDS diagnosis was 37.9 years (SD = ± 9.19), and median
38 years; age on entry to the study was 39.9 years (SD = ± 9.25), and the
median 40 years. Of the patients, 57 (72%) were male and 22 (28%)
female. Of the 79 individuals monitored, 9 (11.4%) died from AIDS-
related causes. The remaining patients were censored: 66 on completion
of the study, 3 for lost follow-up and one for a road accident.
All patients in our study were treated with antiretrovirals. In the
retrospective period, 43 (67%) patients had initiated antiretroviral
treatment with one drug (monotherapy) and in 21 (33%) of them the
initial treatment was the association of two drugs. The drugs available
by the Ministry of Health program were nucleoside reverse transcriptase
inhibitors (NRTI), zidovudine (AZT), didanosine (ddI), dideoxycytidine
(ddC), and lamivudine (3TC). Initial regimens were: AZT in 40 patients
(50.6%), ddI in 3 (3.8%), double combination with AZT and ddI in 18
patients (22.8%), AZT and 3TC in 2 patients (2.5%) and AZT and ddC
in one patient (1.3%).
During the prospective period, 15 naïve patients were included (19%
of the entire cohort). The treatments available at that time were nucleoside
reverse transcriptase inhibitors (NRTI), zidovudine, didanosine,
dideoxycytidine, lamivudine and stavudine, in addiction to the protease
inhibitors (PI) saquinavir, ritonavir, indinavir and nelfinavir. They initiated
their treatments with at least a triple combination as follows: AZT and ddI
plus ritonavir in one case (1.3%), saquinavir in 2 cases (2.6%), indinavir
in 3 cases (3.9%) and nelfinavir in 3 cases (3.9%). 3TC and estavudine
added to indinavir in one (1.3%) case, nelfinavir in 1 (1.3%) case and
ritonavir-saquinavir in one (1.3%) case. AZT and 3TC plus indinavir in 2
cases (2.6%), ritonavir in one case (1.3%) and ritonavir-saquinavir in one
(1.3%) case. The treatment regimens followed varied according to the
clinical indication (respecting Brazilian’s Guidelines), and a triple therapy
was used in almost all patients except in cases requiring rifampicin (n =
6), where the PI was suspended for the 6 months of tuberculosis treatment.
Nevirapin a non nucleoside reverse transcriptase inhibitor (NNRT) became
available during the prospective period.
Incidence of opportunistic diseases: The overall OD rate for the
entire period (from AIDS diagnosis to the end of the study) was 0.39 (CI
= 0.31 - 0.47) per person per year (pp/y). A total of 97 ODs occurred, 56
in the retrospective (before CD4 counts  100 cells/mm3) period and 41
in the prospective (after CD4 counts  100 cells/mm3) period. Of the 79
patients, 26 (32.9%) never suffered from OD at any time during the
natural history of HIV.
PROSPECTIVE PERIOD (after CD4 counts  100 cells/mm3): The
incidence rate of OD in the prospective period was 0.29 per person per
year (CI = 0.21 - 0.39).
We analysed the incidence rates by frequency of aggregate ODs prior
to inclusion in the study (Table 1). OD incidence was thus significantly
higher (p = 0.05) among those individuals with an aggregate of more
than 2 ODs. We also observed that the incidence rate among the patients
with tuberculosis (0.55 pp/year) was nearly twice as high as for those
who did not have tuberculosis  (0.23 pp/year).
Almost surprisingly, start-up of antiretroviral treatment with triple
combinations with PIs (0.54 pp/year) figures as a factor associated with
a significant (p = 0.05) greater morbidity in this period in comparison
with monotherapic regimens (0.25 pp/year, Table 1).
Incidence rates were controlled for other variables for which the
results, although without statistical significance, are given in Table 2.
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Table 1
Incidence (Poisson regression) of opportunistic diseases (OD) according to demographic, clinical and laboratory characteristics in advanced immunodeficiency
– Significant variables for the prospective (after CD4 counts dropped < 100 cells/mm3) period
Variable Category N Incidence of CI P
OD pp/year value
Aggregate  number of 1 OD 16 0.34 0.23-0.52 0.05
OD prior to inclusion in 2 OD 10 0.59 0.22-1.60
the study 3 OD 4 0.78 0.25-2.41
4 OD 2 0.73 0.23-2.36
Tuberculosis diagnosis Yes 14 0.55 0.21-1.54 0.01
(all participants) No 65 0.23 0.17-0.34
initial ARV Monotherapy 43 0.25 0.04-0.32 0.05
treatment HAART 15 0.54 0.04-1.43
N = number; CI= confidence interval; pp/year = per person/year; P values  0.05 were considered statatiscally significant; ARV = antiretroviral
Table 2
Incidence (Poisson regression) of opportunistic diseases according to demographic, clinical and laboratory characteristics in advanced immunodeficiency – Not
significant variables in the prospective period (after CD4 counts < 100cells/mm3)
Variable Category No. of cases Incidence of OD pp/year CI P value
Gender Male 57 0.26 0.18-0.38 0.26
Female 22 0.38 0.13-1.05
Age at inclusion 40 years 42 0.29 0.19-0.44 0.95
>40 years 37 0.29 0.10-0.82
Aids criteria CD4<200 44 0.62 0.39-0.97 0.16
TB 14 0.76 0.22-2.63
Protozoan infection 9 0.54 0.14-2.11
DMAC or CMV 4 1.13 0.21-5.99
Fungal infection 2 2.81 0.61-12.95
Aids defining OD TB 14 0.36 0.19-0.70 0.76
Protozoan infection 9 0.29 0.05-1.55
DMAC or CMV 4 0.61 0.08-4.30
Fungal infection 6 0.43 0.06-2.71
CD4 at entry > 50 cells/mm3 36 0.21 0.07-0.58 0.10
 50 cells/mm3 43 0.35 0.24-0.51
Restoration of CD4 counts No 20 0.41 0.24-0.73 0.17
above 100 cells/mm3 Yes 59 0.26 0.07-0.89
Restoration of CD4 counts No 49 0.27 0.18-0.42 0.66
above 200 cells/mm3 Yes 30 0.31 0.11-0.89
Sustained viral load Yes 22 0.30 0.18-0.51 0.81
Below 10,000 copies No 57 0.28 0.09-0.91
Sustained viral load Yes 30 0.29 0.14-0.40 0.33
Below 30,000 copies No 49 0.33 0.10-1.05
Sustained viral load Yes 47 0.27 0.18-0.42 0.66
Below 100,000 copies No 32 0.31 0.11-0.89
TB diagnosis * Yes 14 0.61 0.22-1.67 0.44
No 65 0.78 0.53-1.13
* excluding patients without OD diagnosis; TB = tuberculosis, Protozoan infection = Pneumocystis, CNS toxoplasmosis, Fungal infection = Histoplasma,
Cryptococcus and esophageal Candidosis
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RETROSPECTIVE PERIOD: The incidence rate of ODs in this
period was 0.51 pp/year (CI = 0.39 - 0.66). Higher incidence of ODs
was observed in individuals whose AIDS diagnosis was established by
OD as compared with diagnosis by CD4+ < 200 cells/mm3, with a value
of p = 0.05 (Table 3).
We determined the incidences of ODs excluding the stratum of
patients diagnosed with AIDS by CD4+ counts, and the results indicate
that the difference observed in the first analysis is not repeated (p =
0.46).
OVERALL SURVIVAL: Mean survival of the entire cohort from
AIDS diagnosis was 2589 days (CI = 2363-2816) equivalent to 7.09
years, and the median was 2916 days (7.98 years).
When CD4+ count used as an inclusion criterion was categorized
into  50 cells/mm3 (n = 43) and 51 - 100 cells/mm3 (n = 36), survival
was significantly longer (p = 0.03), for those with CD4+ counts > 50
cells/mm3 (mean = 2650 days, CI = 2512 - 2788, HR = 0.13) than for
those with CD4+ counts  50 cells/mm3 (mean = 2352, CI = 1956 -
2747).
Survival was also longer for patients whose CD4+ cell counts were
restored to > 100/mm3 during follow-up (n = 59, mean survival = 2769
days; CI = 2583 - 2955), in comparison with those who did not restore (n
= 20, mean survival = 1911 days; CI = 1341 - 2481, p = 0.03, HR = 0.16).
Modelling survival to incorporate all the significant variables
described above revealed that the effect of CD4+ count at inclusion had
become insignificant (HR = 0.24; CI = 0.03 - 2.01, p = 0.19), while the
HR for those with restored CD4+ counts was 0.22, and significant (CI =
0.05 - 0.93, p value = 0.04).
We evaluated plasma viral load throughout the study at three cut-off
points and observed no differences among the categories evaluated – (a)
< 10,000 copies, mean survival = 2663 days (CI = 2261-3064, n = 22)
and  10,000, mean = 2140 days (CI = 1939 - 2348, n = 57); (b) <
30,000, mean = 2635 days (CI = 2294 - 2976, n = 30) and  30,000,
mean = 2136 days (CI = 1910 - 2361); and (c) < 100,000, 2661 days (CI
= 2356-2886, n = 32) and  100,000, mean = 2098 (CI = 1777 - 2418).
Other variables were not statistically significant in survival: AIDS
diagnosis by immunological criteria, CD4+ < 200 cells/mm3 (mean =
Table 4
Incidence (Poisson regression) of opportunistic diseases according to demographic, clinical and laboratory characteristics in advanced immunodeficiency
– Not significant variables for the retrospective period (before CD4 counts dropped < 100 cells/mm3)
Variable Category No. of cases Incidence of OD pp/year CI P value
Aids defining OD TB 17 0.71 0.46-1.08 0.46
Protozoan infection 12 0.87 0.30-2.57
DMAC or CMV 11 1.71 0.38-7.61
Fungal infection 12 1.01 0.29-3.51
TB diagnosis No 65 0.74 0.29-1.87 0.47
* excluding patients Yes 14 0.89 0.60-1.34
without OD diagnosis
TB = tuberculosis, Protozoan infection = Pneumocystis, CNS toxoplasmosis; DMAC = disseminated Mycobacterium avium complex;  CMV = Cytomegalovirus;
Fungal infection = Histoplasma, Cryptococcus and esophageal Candidosis
Table 3
Incidence (Poisson regression) of opportunistic diseases according to demographic, clinical and laboratory characteristics in advanced immunodeficiency
– Significant variables for the retrospective (before CD4 counts dropped < 100 cells/mm3) period
Variable Category N Incidence of OD pp/year CI P value
AIDS criteria CD4< 200 44 0.13 0.04-0.39 0.05
TB 17 0.71 0.14-0.39
Protozoan infection 12 0.87 0.17-4.45
DMAC or CMV 11 1.70 0.24-12.21
Fungal infection 12 1.01 0.17-5.87
TB diagnosis Yes 14 0.36 0.24-0.54 0.01
(all  participants) No 65 0.76 0.29-1.84
N = number of cases; pp/year = per person/year; CI = Confidence interval;  P values  0.05 were considered statatiscally significant; TB = Tuberculosis; Protozoan
infection = Pneumocystis; DMAC = disseminated Mycobacterium avium complex; CMV = Cytomegalovirus; Fungal infection = Histoplasmosis, Cryptococcosis and
esophageal Candidosis;  CI =  confidence interval
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2466 days, CI = 2086 - 2847) if compared with diagnosis by OD (mean
= 2373 days, CI = 2200 - 2547, p = 0.35), prior use of monotherapy
(mean = 1276 days, CI = 1168 - 1384) compared with the start of
treatment with associations of two or three drugs (mean = 2631 days, CI
= 2375 - 2887), in addition to sex and age at AIDS diagnosis.
SURVIVAL DURING THE PROSPECTIVE PERIOD: We
described survival and the factors associated with it from the moment
when patients were considered severely immunodepressed, at the point
their CD4+ count fell below 100 cells/mm3. Overall mean survival was
1376 days (CI = 1181 - 1572).
Survival was similar among men and women and was neither
associated with the age, the AIDS-defining criteria, aggregate diseases
prior to inclusion in the study, baseline CD4 counts, viral load or the
initial antiretroviral treatment (Table 5).
We found however, longer survival among 59 individuals whose
counts were restored to > 100 cells/mm3 as compared with  those whose
counts were not restored (Fig. 1). At the 200-cell cut-off point, however,
this effect becomes less evident (Table 5).
The model that included the variables restoration of CD4+ cells with
a 100-cell cut-off point and counts at time of inclusion in the study with
a 50-cell/mm3 cut-off point indicated that restoration of cells (HR = 0.21,
CI = 0.05 - 0.93) continued significant (p = 0.05), while count at start of
the study (HR = 0.19, CI = 0.02 - 1.59) lost statistical significance (p =
0.12). The variable determinant of longer survival was restoration of
CD4+ count to values > 100 cells/mm3.
DISCUSSION
Our study started at almost the same time as antiretrovirals became
Table 5
Survival  according to demographic, clinical and laboratory characteristics in advanced immunodeficiency (after CD4 dropped below 100 cells/mm3 -
prospective period)
Variable Category No. of cases Mean survival CI Log rank p value
Gender Male 57 1424 1221-1626 0.57
Female 22 1023 880-1166
Age at inclusion  40 years 42 1074 958-1190 0.64
> 40 years 37 1417 1191-1644
Aids criteria CD4 < 200 44 1603 1495-1711 0.16
OD 35 1180 969-1391
Aggregate N of OD prior no OD 47 1606 1495-1711
to inclusion in the study 1 and 2 OD 26 1112 982-1242 0.11
3 and 4 OD 6 966 401-1532
CD4 at entry > 50 cells/mm3 36 1655 1564-1746 0.09
 50 cells/mm3 43 1201 1035-1367
Restoration of CD4 counts no 20 1489 1298-1680 0.01
above 100 cells/mm3 yes 59 796 683-908
Restoration of CD4 counts no 49 1166 0.10
above 200 cells/mm3 yes 30 1601
Sustained viral load yes 22 1437 1201-1673 0.54
Below 10000 copies no 57 1018 922-1114
Sustained viral load yes 30 1419 1193-1645 0.75
Below 30000 copies no 49 1022 923-1121
Sustained viral load yes 47 0.27 0.18-0.42 0.66
Below 100000 copies no 32 0.31 0.11-0.89
Initial ARV treatment monotherapy 43 1398 1189-1608 0.96
HAART 15 880 824-935
N = number, CI = Confidence interval , OD = opportunistic diseases, ARV = antiretroviral, HAART = higly active antiretroviral therapy
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available and as viral load tests were made simultaneously with CD4+
counts19. The results of these measures, such as reduced occurrence of
ODs and increased survival, were quickly perceived by the researchers
involved in our protocol, as by all health workers responsible for caring
for those with HIV/AIDS in Brazil18. The same has been observed in
other parts of the world5,10, 23.
When survival from AIDS diagnosis was considered, we found a
low death rate, given that the deaths only began to occur following
inclusion in the study at a time when the individuals were already at an
advanced stage of immunodeficiency, and treated with HAART.
The median survival time for the whole cohort, from AIDS diagnosis
up until the end of the study, was 7.09 years. This is an extremely long
period when compared with other studies in Brazil, where the period
between AIDS diagnosis and death varied from 4.9 months to 9.15
months9,12. In another more recent Brazilian study, which differentiated
by gender, survival of 20 months was observed for men and 11 months
for women26. Even studies prior to the introduction of PIs in Europe and
the United States encountered post-AIDS survival shorter than our results,
viz. Australia, 14.4 months13 and 15 months7, San Francisco 12.5
months11, Denmark 13.0 months24 and New York, 13.7 months1.
In addition to the effect of HAART, the criteria for inclusion in our study
may have led to a selection bias towards individuals who had already survived
with AIDS for a reasonably long time before inclusion in our cohort. Also, the
CPqHEC is a centre specializing in research and treatment for individuals
with HIV/AIDS, where adhesion to proposed appointments and treatments is
good, and where these individuals receive multidisciplinary care and are treated
free of charge, not just for HIV, but also for associated ODs.
From 1997 onwards, some authors showed a decline in AIDS-related
mortality, which was attributed to antiretroviral therapy with protease
inhibitors5,10 and longer survival times, thus similar to our results14.
In the prospective period of the study (after CD4 counts < 100 cells/
mm3), the incidence rate of opportunistic diseases (0.29 pp/y) was almost
half that observed in the retrospective period (before CD4 counts < 100
cells/mm3 = 0.51 pp/y), which we consider the opposite of what one
might expect on the basis that advanced immunodeficiency should be
associated with higher rates. We attribute this finding to the use of HAART
during the prospective period. Other authors also describe a decrease in
morbidity associated with the use of PIs in several countries10,17,23.
Our study showed no significant difference in OD incidence and
survival among women and men under or over 40 years old. Although
some studies have evaluated the role of age and gender in the prognosis
for morbidity and mortality from ODs10,23, and no association has been
established between these two factors, CHAISSON et al. argues that
this finding in other studies reflects differences in access to health services
and not in demographic features5. One recent study, which evaluated
survival among men and women, showed shorter survival times among
women that were not explained by differences in access to health services,
and pointed to a lower CD8+ cell counts among women as being the
main factor implicated26.
In the cases we studied, the AIDS diagnosis by disease was
significantly (p < 0.05) associated with greater morbidity from OD in
the retrospective period as compared with diagnosis by CD4+ < 200
cells/mm3. In 1999, LEDERGERBER et al. also showed a risk of disease
2.5 times higher in patients whose AIDS diagnosis was established by
OD10. However, survival does not appear to be influenced by these factors
in our study, given that these events preceded inclusion in the protocol
by several years, and lose force over time.
Although the results presented show a strong relationship between
the aggregate quantity of OD during the retrospective period and
morbidity during the prospective period, no significant differences in
survival was detected.
In the pre-HAART era, some studies suggested that the higher
aggregate number of ODs in the course of AIDS was associated with
higher risk of death20, while others observed that the prognosis for patients
with other associated ODs was not necessarily worse than for those with
a single disease13. More recent studies show that the severity associated
with each individual OD continues to influence the prognosis over time10,
in addition to determining greater risk of incidence of other ODs8.
However, these studies did not evaluate aggregate OD, because the
patients were included in those studies at an early stage of HIV infection
and thus without any significant aggregate of OD.
Baseline CD4+ cell count showed a strong association with survival,
which was not shown with morbidity. Many authors have evaluated the
role of CD4+ cell counts in the prognosis of death5,10, but few have tested
the factors associated with ODs incidence.
The very low incidence of ODs and the small number of participants,
as compared with other cohorts in multicentre studies, may have
contributed to this association not being detected in our study.
We also evaluated the effect of reconstitution of the immune system
by categorizing individuals whose CD4+ cells were or were not restored
to levels of > 100 cells/mm3, again finding a strong association with
Fig. 1 - Survival (Kaplan Meier) from AIDS diagnosis in patients whose CD4 counts were
restored to above 100 cells/mm3 and those whose counts remained below 100 cells/mm3
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survival, but not with morbidity. We evaluated restoration of the immune
system at another cut-off point (CD4+ > 200 cells/mm3) to determine, as
other authors have done5, whether the effect would be stronger at higher
CD4+ levels, but observed no statistically significant differences in
morbidity at this cut-off point.
No differences were observed in OD rates or in survival according
to viral load at the 10,000-copy, 30,000-copy or 100,000-copy cut-off
points. Other studies to evaluate the value viral have shown that ODs
have been associated with higher viral loads and with progression to
other ODs10.
In the cases we studied, the use of monotherapy was associated with
lower OD rates than triple therapy. Our including individuals with at
least one CD4+ cell count  100 cells/mm3 resulted in a selection bias
towards individuals who had survived for a long time with severe
immunodeficiency on monotherapy or double therapy. Meanwhile,
patients included in our study who initially used triple treatments (15%)
were diagnosed as AIDS cases by disease, already with severe
immunodeficiency (CD4 counts below 100 mm3) and most of the times
with other OD diagnoses which led to an association, at the time of
inclusion in the study, between the start of HAART and ODs morbidity.
When we evaluated the effect of these treatments in survival, we
observed that although a trend to survive longer was observed among
those who used double or triple treatment as the initial regimen, this
difference was not statistically significant.
Antiretroviral treatment has been evaluated in other studies, and its
protective role has been very clearly demonstrated in studies of large
numbers of cases, which noted a relationship between intensification of
the treatment (inclusion of PIs) and improved prognosis2,17.
In conclusion, our study observed a reduction in OD incidence after
CD4 counts dropped below 100 mm3, time almost all patients were under
HAART. We also observe the protective role of reconstituting CD4 cells
in survival. These effects were associated with the use of highly active
antiretroviral treatment jointly with the prophylaxis for OD such as
Pneumocystis carinii pneumonia (PCP) neurotoxoplasmosis and
tuberculosis which is routine practice at our Centre.
RESUMO
Morbidade e sobrevida em AIDS avançada no Rio de Janeiro,
Brasil
As doenças oportunistas (DO) são a causa mais comum de morte em
pacientes com AIDS. Para acessar a incidência de DO e a sobrevida na
imunodeficiência avançada, foram incluídos 79 pacientes com AIDS
tratados no Hospital Evandro Chagas (FIOCRUZ) no período de
Setembro de 1997 a Dezembro de 1999, com ao menos uma contagem
de células CD4  100/mm3. A incidência de DO foi analisada pela
regressão de Poisson e a sobrevida pela analise de Kaplan Meier e Cox,
considerando um período retrospectivo (anterior à contagem de CD4 
100 cels/mm3) e um prospectivo (após a contagem de CD4  100 cels/
mm3) e controlando-se características demográficas clínicas e
laboratoriais. O intervalo de confiança estipulado foi o de 95%.
O período médio de acompanhamento foi de 733 dias (IC = 683 - 782).
Durante o estudo, nove (11,4%) pacientes morreram. A sobrevida a partir
do diagnóstico de AIDS foi em média de 2589 dias (IC = 2363 - 2816) e da
data da contagem de CD4  100 cels/mm3 foi em média de 1376 dias (IC =
1181 - 1572). A incidência de DO foi de 0,51 pp/ano no período pré-CD4 
100 cels/mm3 e 0,29 pp/ano no período pós-CD4  100 cels/mm3. Um menor
número de DO acumuladas no período pré-CD4  100 cels/mm3 foi associado
com taxas de incidência menores no período pós-CD4  100 cels/mm3. O
diagnóstico de AIDS baseado em contagem de CD4+  200 cels/mm3 foi
associado com menores taxas de incidência durante o período pós-CD4 
100 cels/mm3. As contagens basais de células CD4 acima de 50 cel/mm3
(HR = 0,16) foram associadas a um menor risco de morte assim como a
restauração da contagem basal acima de 100 cels/mm3 (HR = 0,16).
Controlando-se ambas, somente a restauração da contagem basal manteve
sua significância estatística (HR = 0,22, p = 0,04)
Encontramos uma baixa incidência de DO durante o período pós-
CD4  100 cels/mm3 e uma sobrevida longa após CD4  100 cels/mm3.
A sobrevida foi significativamente associada com a restauração das
contagens de CD4 basais.
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